215 related articles for article (PubMed ID: 34219488)
21. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
22. Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema.
Maggio E; Mete M; Sartore M; Bauci F; Guerriero M; Polito A; Pertile G
Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):807-815. PubMed ID: 34661731
[TBL] [Abstract][Full Text] [Related]
23. RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better.
Ebneter A; Wolf S; Abhishek J; Zinkernagel MS
Retina; 2016 Jul; 36(7):1314-23. PubMed ID: 26735563
[TBL] [Abstract][Full Text] [Related]
24. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
[TBL] [Abstract][Full Text] [Related]
25. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.
Zur D; Iglicki M; Busch C; Invernizzi A; Mariussi M; Loewenstein A;
Ophthalmology; 2018 Feb; 125(2):267-275. PubMed ID: 28935399
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of inner and outer retinal thickness in patients receiving intravitreal ranibizumab injections for diabetic macular edema.
Dursun A; Ozec AV; Kirboga K; Dursun FG; Toker MI; Erdogan H; Arici MK
Eur J Ophthalmol; 2016; 26(1):48-53. PubMed ID: 26220809
[TBL] [Abstract][Full Text] [Related]
27. Comparison of intravitreal ranibizumab, aflibercept and bevacizumab therapies in diabetic macular edema with serous retinal detachment.
Sirakaya E; Kilic D; Aslan Sirakaya H
Eur J Ophthalmol; 2023 May; 33(3):1459-1466. PubMed ID: 36482707
[TBL] [Abstract][Full Text] [Related]
28. Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
Hwang HS; Chae JB; Kim JY; Kim DY
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5958-5967. PubMed ID: 29183041
[TBL] [Abstract][Full Text] [Related]
29. Short-term outcomes of intravitreal dexamethasone in relation to biomarkers in diabetic macular edema.
Narnaware SH; Bawankule PK; Raje D
Eur J Ophthalmol; 2021 May; 31(3):1185-1191. PubMed ID: 32429696
[TBL] [Abstract][Full Text] [Related]
30. Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China.
Liu S; Wang D; Chen F; Zhang X
BMC Ophthalmol; 2019 Jul; 19(1):157. PubMed ID: 31337360
[TBL] [Abstract][Full Text] [Related]
31. Factors predicting the treatment frequency of ranibizumab injections during the second year in diabetic macular edema.
Nishikawa K; Murakami T; Ishihara K; Dodo Y; Terada N; Morino K; Tsujikawa A
Jpn J Ophthalmol; 2022 May; 66(3):296-304. PubMed ID: 35438397
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema.
Mahapatra SK; Parhi A; Shree P; Mohanty A
Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S106-S110. PubMed ID: 38131551
[TBL] [Abstract][Full Text] [Related]
33. Clinical Characteristics and Long-term Outcomes in Diabetic Macular Edema Patients: With or without Additional Injection Following Ranibizumab Loading.
Yoon K; Kim ES; Yu SY; Kim K
Korean J Ophthalmol; 2022 Oct; 36(5):398-406. PubMed ID: 35989066
[TBL] [Abstract][Full Text] [Related]
34. Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema.
Mori Y; Murakami T; Suzuma K; Ishihara K; Yoshitake S; Fujimoto M; Dodo Y; Yoshitake T; Miwa Y; Tsujikawa A
PLoS One; 2017; 12(4):e0175809. PubMed ID: 28407012
[TBL] [Abstract][Full Text] [Related]
35. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
Seo KH; Yu SY; Kim M; Kwak HW
Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
[TBL] [Abstract][Full Text] [Related]
36. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal Ranibizumab Alone or in Combination with Calcium Dobesilate for the Treatment of Diabetic Macular Edema in Nonproliferative Diabetic Retinopathy Patients: 12-Month Outcomes of a Retrospective Study.
Wang D; Wang H; Wu S; Yang X; Xu J
Int J Clin Pract; 2022; 2022():6725225. PubMed ID: 36340967
[TBL] [Abstract][Full Text] [Related]
38. INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study.
Comet A; Gascon P; Ramtohul P; Donnadieu B; Denis D; Matonti F
Eur J Ophthalmol; 2021 Mar; 31(2):754-758. PubMed ID: 32507032
[TBL] [Abstract][Full Text] [Related]
39. Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema.
Yigit K; Inan ÜÜ; Inan S; Dogan M; Yavas GF; Cetinkaya E
Int Ophthalmol; 2021 Apr; 41(4):1487-1501. PubMed ID: 33486648
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results.
Türkseven Kumral E; Erçalık NY
Semin Ophthalmol; 2021 Nov; 36(8):723-727. PubMed ID: 33760698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
